Nucelion Therapeutics, VeGen Bio Partner on CAR-T Therapy The Story: Nucelion Therapeutics and VeGen Bio have partnered to transfer technology and manufacture VL-2511, a Phase II dual-target CAR-T the...
Key Highlights: Implications: Mankind Pharma’s €48 million investment for a 70% stake in ACTx signals a strategic shift toward high-value oncology and next-generation CAR-T therapies. ACTx...
Dr. Reddy’s Signs License Deal for Once-Yearly Lenacapavir The Story:Dr. Reddy’s has signed a royalty-free, non-exclusive license agreement with Gilead Sciences for investigational once-yearly lenacap...
Key Highlights: Implications: Dr. Reddy’s launch of Nivorz marks its entry into India’s biosimilar immuno‑oncology segment and adds a lower‑cost checkpoint inhibitor option across 12 appro...
Key Highlights: Implications: The deal adds ~$90–100 million of annualized revenue visibility from 2029, diversifies Gland’s customer base, and strengthens its credibility as a o...
Key Highlights: Implications: By consolidating three injectable-focused entities under one legal umbrella, Aurobindo can streamline manufacturing, R&D, and commercial operati...
Key Highlights: Implications: The approval broadens AstraZeneca’s trastuzumab deruxtecan franchise in India from later-line metastatic use into the earlier, potentially larger HER2-positiv...
Key Highlights: Implications: Relopduo gives BMS a next‑generation immunotherapy in India’s melanoma market, combining PD‑1 and LAG‑3 blockade to offer materially better pro...
Latest Developments in Cell and Gene Therapy Manufacturing Cell and gene therapies are rapidly emerging as one of the most transformative areas in modern medicine. These advanced therapies aim t...
Key Highlights: Implications: GTBL’s MicroBiopharm acquisition is a strategic move to become a more integrated, higher-value pharma services and ingredients player. The mai...
